Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
40
OVID Quote, Financials, Valuation and Earnings
Last price:
$1.79
Seasonality move
:
-12.18%
Day range:
$1.77 - $1.88
52-week range:
$0.24 - $2.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.14x
P/B ratio:
2.84x
Volume:
1.1M
Avg. volume:
1.8M
1-year change:
84.21%
Market cap:
$126.8M
Revenue:
$566K
EPS (TTM):
-$0.51
Analysts' Opinion
-
Consensus RatingOvid Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.05, Ovid Therapeutics, Inc. has an estimated upside of 127.47% from its current price of $1.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing -12.36% downside risk from its current price of $1.78.
Fair Value
-
According to the consensus of 11 analysts, Ovid Therapeutics, Inc. has 127.47% upside to fair value with a price target of $4.05 per share.
OVID vs. S&P 500
-
Over the past 5 trading days, Ovid Therapeutics, Inc. has overperformed the S&P 500 by 18.58% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ovid Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ovid Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ovid Therapeutics, Inc. reported revenues of $132K.
Earnings Growth
-
Ovid Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Ovid Therapeutics, Inc. reported earnings per share of -$0.17.
Enterprise value:
114.9M
EV / Invested capital:
1.97x
Price / LTM sales:
19.14x
EV / EBIT:
--
EV / Revenue:
17.39x
PEG ratio (5yr expected):
-0.31x
EV / Free cash flow:
-3.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$6.2M
Return On Assets:
-43.48%
Net Income Margin (TTM):
-549.62%
Return On Equity:
-59.7%
Return On Invested Capital:
-48.14%
Operating Margin:
-9487.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $296.4K | $631.6K | $6.6M | $173K | $132K | |
| Gross Profit | -$1.3M | -$222.8K | $6.2M | $4K | $115K | |
| Operating Income | -$53.3M | -$69.3M | -$40.9M | -$13.2M | -$12.5M | |
| EBITDA | -$51.6M | -$68.5M | -$40.5M | -$13.1M | -$12.5M | |
| Diluted EPS | -$0.69 | -$0.46 | -$0.51 | -$0.20 | -$0.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $205.1M | $140.5M | $91.7M | $65.8M | $28.8M | |
| Total Assets | $207.1M | $165M | $125M | $102.7M | $63.8M | |
| Current Liabilities | $10.1M | $6.7M | $8.7M | $11.6M | $6.8M | |
| Total Liabilities | $10.1M | $23M | $23.7M | $26.4M | $19.2M | |
| Total Equity | $197M | $142.1M | $101.3M | $76.3M | $44.7M | |
| Total Debt | -- | $16.2M | $15.1M | $14.7M | $12.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$43M | -$57.9M | -$37.9M | -$15M | -$12.9M | |
| Cash From Investing | $41.8M | -$15.2M | $43.5M | $292K | $5.1M | |
| Cash From Financing | $458.2K | $30.7M | $28K | $38K | $15K | |
| Free Cash Flow | -$43.2M | -$57.9M | -$37.9M | -$15M | -$12.9M | |
OVID
Sector
Market Cap
$126.8M
$28.1M
Price % of 52-Week High
88.56%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
0.53%
-1.49%
1-Year Price Total Return
84.21%
-17.13%
Beta (5-Year)
0.045
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.60
200-day SMA
Buy
Level
$0.86
Bollinger Bands (100)
Buy
Level
1.05 - 1.67
Chaikin Money Flow
Buy
Level
1.1M
20-day SMA
Buy
Level
$1.62
Relative Strength Index (RSI14)
Buy
Level
60.19
ADX Line
Buy
Level
16.86
Williams %R
Sell
Level
-16.129
50-day SMA
Buy
Level
$1.51
MACD (12, 26)
Buy
Level
0.07
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
53.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.5789)
Sell
CA Score
(Annual)
Level (-2.0891)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.5086)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During on April 1, 2014 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, OVID has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OVID average analyst price target in the past 3 months is $4.05.
-
Where Will Ovid Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ovid Therapeutics, Inc. share price will rise to $4.05 per share over the next 12 months.
-
What Do Analysts Say About Ovid Therapeutics, Inc.?
Analysts are divided on their view about Ovid Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ovid Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Ovid Therapeutics, Inc.'s Price Target?
The price target for Ovid Therapeutics, Inc. over the next 1-year time period is forecast to be $4.05 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OVID A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ovid Therapeutics, Inc. is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OVID?
You can purchase shares of Ovid Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ovid Therapeutics, Inc. shares.
-
What Is The Ovid Therapeutics, Inc. Share Price Today?
Ovid Therapeutics, Inc. was last trading at $1.79 per share. This represents the most recent stock quote for Ovid Therapeutics, Inc.. Yesterday, Ovid Therapeutics, Inc. closed at $1.78 per share.
-
How To Buy Ovid Therapeutics, Inc. Stock Online?
In order to purchase Ovid Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OVID Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OVID
Sector
P/E ratio
--
23.89x
PEG ratio
-0.31x
-0.01x
P/B ratio
2.84x
1.81x
Price / LTM sales
19.14x
1.59x
Growth Metrics
OVID
Sector
Revenue growth
-23.7%
4.62%
Earnings growth
13.33%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.15
-$0.21
Profitability
OVID
Sector
Profitability FY 2024
-$34K
$3.6M
Return on invested capital
-48.14%
-31.84%
Return on assets
-43.48%
-27.96%
Return on equity
-59.7%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
11
Balance Sheet
OVID
Sector
Total cash
$25.6M
$26.4M
Short term investments
$26.8M
$25.7M
Total assets
$92.2M
$76.9M
Long term debt
$12.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
